Germany
· Delayed Price · Currency is EUR Liquidia Company Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD.
Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
| Country | United States |
| Founded | 2004 |
| Industry | Pharmaceutical Preparations |
| Employees | 170 |
| CEO | Roger Jeffs |
Contact Details
Address: 419 Davis Drive Morrisville, Delaware 27560 United States | |
| Phone | 919 328 4400 |
| Website | liquidia.com |
Stock Details
| Ticker Symbol | LT4 |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Roger Jeffs | Chief Executive Officer |
| Michael Kaseta | Chief Financial Officer |
| Michael Kaseta | Chief Operating Officer |